News

Merck said that the DEFINE trial was an 18-month study in more than 1,600 patients with or at high risk for CHD who were already receiving statins and

In the current trial, the patients received four standardised doses of ToleroMune T-cell vaccine over a number of weeks. During the study, investigators administered a challenge dose of

The trial demonstrate the potent and consistent antiviral efficacy of TMC435 in patients who had failed earlier treatment with peg-IFN and ribavarin (standard of care), as well as

These generic Clarinex tablets contain desloratidine 5mg. Sun Pharma said that Clarinex is a prescription medication, treats year-round allergy symptoms and ongoing hives of unknown cause, in adults

The Phase III trial is designed to evaluate the therapeutic effects of Cladribine tablets on the time to conversion to multiple sclerosis (MS) in people with a first

Sun Pharma said that these generic Tiazac capsules contain Diltiazem Hydrochloride extended-release USP, 120mg, 180mg, 240mg,300mg and 360mg, and are therapeutically equivalent to Biovail’s Tiazac extended release capsules.

Bioniche said that the current milestone payment was triggered by Urocidin attaining a contractual efficacy goal from an ongoing US Food and Drug Administration (FDA) Phase III registration

Bromday (formerly referred to as XiDay), an once-daily prescription eye drop for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract

The company said that the new patent will expire in 2023. RegeneRx claims that it holds patents and patent applications worldwide related to its products and holds an